Medi-Cal Rx transition policy retirement for beneficiaries 22+ years old

Provider Icon

On June 23, 2023 the Transition Policy for 46 drug classes will be retired. Prior authorizations will once again be required for the following 46 drug classes.

Phase III, Lift 4 Drug Classes
Medical Supplies Chloramphenicol Enzymes
Emetics Antineoplastics Rauwolfias
Antidiarrheals Trimethoprim Vasodilators Peripheral
Antispasmodic and Anticholinergic Agents Contraceptives, Non-Systemic Xanthine Derivatives
Bile Therapy Vaginal Cleansers Hemostatics
Laxatives Diagnostics B-Complex with Vitamin C
Ataractics-Tranquilizers (remaining HIC3s) Anesthetics Gen Inhalant (remaining HIC3s) Hematinics and Blood Cell Stimulators
CNS Stimulants Anesthetics Gen Inject Allergens
Psychostimulants-Antidepressants Sedative Barbiturate Antipruritics
Amphetamine Preparations Sedative Non-Barbiturate (remaining HIC3s) Coal Tar
All Other Antiobesity Preps Anticonvulsants (remaining HIC3s) Hemorrhoidal Preparations
Antihistamines Antinauseants Oxytocics
Bronchial Dilators Mineralocorticoids Parasympathetic Agents
Cough Preparations/ Expectorants Antidotes Miscellaneous


Cold and Cough Preparations Antithyroid Preps
Adrenergics Digestants

Please note that the following are exempt from Phase III: Retirement of the Transition Policy:

  • Beneficiaries 21 years of age and younger.
  • Enteral nutrition products for beneficiaries of all ages.

What pharmacy providers and prescribers need to do

If a beneficiary is currently receiving a medication in a drug class listed in the table, pharmacy providers and prescribers can consider the following options:

  1. Consider covered therapies that may not require a PA, if clinically appropriate. Review the following:
  1. If a change in therapy is not appropriate, submit a PA request via one of the approved Medi-Cal Rx submission methods:

You can find additional resources in the DHCS notification.


Call the Medi-Cal Rx Customer Service Center at 800-977-2273 (available 24/7) or email Medi-Cal Rx Education & Outreach at [email protected].